Loading clinical trials...
Loading clinical trials...
Cardiovascular toxicity of carfilzomib, a last generation proteasome inhibitor, is highly incident according to retrospective data. Prospective cohort study of patients initiated on carfilzomib.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
European Georges Pompidou Hospital
NCT07053436 · High Risk Newly Diagnosed Multiple Myeloma
NCT06615479 · Relapsed or Refractory Multiple Myeloma (RRMM)
NCT02417740 · Cystic Fibrosis, Immunologic Deficiency Syndrome, and more
NCT07365332 · Pulmonary Arterial Hypertension
NCT07218029 · Pulmonary Arterial Hypertension
Assistance Publique Hôpitaux de Paris - Centre Université de Paris
Paris
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions